NextCure, Inc., a newly formed biopharmaceutical company focused on the discovery and development of new immuno-oncology products, raised $67m in Series A financing. Backers included Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer, Sofinnova Ventures, and Alexandria Venture Investments. In conjunction with the funding, David Kabakoff, Ph.D., executive partner of Sofinnova Ventures, will join Chairman of the company.
“This deal confirms the critical importance of Dr. Chen’s contributions to the growing field of immuno-oncology,” says Jon Soderstrom, Managing Director of the Yale Office of Cooperative Research (OCR) which played an active role in constructing the deal. “We are confident that this will help usher in a new era of cancer treatment.”